PubMed Health⌕ Search

Biomedical subjects

M Corsi

Publications and source records attributed to M Corsi.

At least 91 records · Page 5Linked to original sources
PubMed1990

Propionyl carnitine in stable effort angina.

The aim of this study was to investigate the anti-ischemic activity of propionyl carnitine (PC) in 18 informed, volunteer male patients, aged 37-70, suffering from a typical stable effort angina. The study design was randomized, balanced, crossover, and double blinded. The study lasted 75 days. In the first 15 days of washout the patients performed two maximal symptom-limited bicycle tests to verify the repeatability of the parameters examined. Then one group received PC for 30 days 500 mg three times a day, and the other group received placebo (PL) three times a day. At the end of 30 days the groups exchanged treatments. At the end of each period, 2 hours after the last oral administration, the patients performed a maximal symptom-limited bicycle exercise test with increased loads of 10 watts/min. No significant differences were observed between the two tests performed during the wash-out period, for a 1 mm ST-segment depression time, for the time to the end of exercise, and for the rate x pressure product at the same experimental time. The oral administration of PC in coronary patients increased both the 1 mm ST-segment depression time and the time to the end of exercise. Furthermore, the drug reduced the ischemic depression of ST at maximal common work and at maximal work. After PC, the rate x pressure product was not significantly different in relation to placebo at submaximal and maximal exercise. Thus PC seems to have an antiischemiclike effect, probably related to its metabolic activity.

Administration, Oral↗
PubMed1990

Effects of a new 1,4-dihydropyridine, lacidipine, on gastrointestinal motility and other gastrointestinal functions.

Lacidipine is a new 1,4-dihydropyridine calcium entry blocker endowed with slow onset of action and potent and long-lasting antihypertensive activity. This study investigated the effect of lacidipine on some gastrointestinal functions, mainly gastrointestinal motility, in rats and dogs. In fasting conscious dogs chronically fitted with electrodes and strain gauges along the small bowel, lacidipine (12 micrograms/kg i.v. bolus or 10 micrograms/kg/h for 3 h) did not modify the migrating motor complex pattern or intestinal spike activity. In the rat, lacidipine proved less active (ED 50 greater than 100 mg/kg p.o.) than nitrendipine (ED 50 = 31 mg/kg p.o.) in inhibiting gastric emptying of a liquid meal, whereas the opposite was true after a solid meal (ED 50 = 10.9 and 35.0 mg/kg p.o., respectively). Lacidipine inhibited fecal pellet output at lower doses (ED 50 = 14.8 mg/kg p.o.) than nitrendipine (ED 50 = 40.1 mg/kg p.o.). On histamine-induced gastric acid secretion, the effect of 100 micrograms/kg i.v. lacidipine was moderate (maximum inhibition 45%). The gastrointestinal effects displayed by lacidipine appear at doses at least 5 and 50 times as high as those affecting blood pressure after intravenous and oral administration, respectively. Thus, lacidipine is unlikely to cause noteworthy unwanted effects on the gastrointestinal tract.

Animals↗
PubMed1990

Morphometric evidence of the trophic effect of L-carnitine on human skeletal muscle.

We investigated the effect of long-term i.v. administration of L-carnitine on human muscle fibers using morphometric parameters. We administered 2g/day L-carnitine to patients undergoing hemodialysis for at least 12 months. At the end of this period a marked increase in serum and muscle carnitine levels was observed in all patients, together with hypertrophy and predominance of type 1 fibers. L-carnitine was withheld for 4 months, during which time serum and muscle levels gradually decreased and no changes were observed in muscle fibers. Subsequent addition of L-carnitine to dialysis fluid for another 4 months stabilized lower levels. At the end of this period reduction of diameter of type 1 fibers was observed. Type 2 fibers remained unchanged. Moreover, type 1 fibers remained predominant in all cases. Hence, we suggest that carnitine has a specific trophic effect on type 1 fibers which are characterized by an oxidative metabolism.

Aged↗
PubMed1990

Morphological study of extraocular muscle proprioceptor alterations in congenital strabismus.

The sensorial structures located at the myotendinous junction of the extraocular muscles of patients suffering from congenital strabismus have been studied. Important alterations of these receptors have been observed, both at light and electron microscopy. The receptors appear smaller, with an inner capsule dividing the tendinous component into irregularly shaped compartments. At electron microscopy it is possible to identify: (1) receptors still possessing their architecture and nerve component but with modified nerve ending features and relationship with the Schwann cell covering; (2) receptors maintaining their general architecture but completely lacking the nerve component; (3) receptors where also the general architecture is completely disorganized. All these alterations seem to indicate that in strabismics the reception and transmission of proprioceptive information are abnormal and support the hypothesis that a disturbance of ocular proprioception can play an important role in the pathogenesis of congenital strabismus.

Adolescent↗
PubMed1990

[Ultrasonic study of the dimensions of the common bile duct in various postures].

To date, the importance of patient position has not been considered in defining the normal range of the internal diameter of the main bile duct. The authors examined 160 patients to verify if significant changes in the internal diameter of the main bile duct take place when changing patient position. In 20/160 cases (12.5%) internal diameter was observed to decrease by greater than 1 mm, in 6/160 cases (3.75%) by greater than 2 mm. These changes were found more often in cholecystectomized patients and were mostly associated with an increase in the max absolute caliber of the main bile duct. Therefore, postural changes (dorsal decubitus, left lateral decubitus, upright position) of the patient are important factors when calculating max internal diameter of the main bile duct. Moreover, postural changes may play an analogous role to functional tests.

Common Bile Duct↗
PubMed1989

L-carnitine addition to dialysis fluid. A therapeutic alternative for hemodialysis patients.

L-Carnitine has been reported to have beneficial effects in the reduction of serum triglycerides and increases high-density lipoprotein cholesterol in hemodialysis patients. The published reports are, however, equivocal. Paradoxical increases in serum triglycerides following intravenous administration of L-carnitine have been observed. It has been suggested that the paradoxical rise in triglycerides may result from the high doses used and intravenous administration, both of which may cause abnormally high tissue concentrations. In the present study 22 hemodialysis patients were selected. All patients had been treated intravenously with 2 g of L-carnitine administered at the end of dialysis for a minimum of 12 months. Treatment with L-carnitine was then discontinued during a 4-month washout period. The patients were then divided into two equal subgroups and placed on L-carnitine therapy (1 g i.v.) at the end of dialysis for 1 month. Thereafter, L-carnitine was added to the dialysate (2 g in group 1, 4 g in group 2) for 3 months. Serum and muscle carnitine levels were determined throughout the study as were lipid parameters, serum chemistry, and hematology. Muscle biopsies obtained at baseline revealed supranormal levels of carnitine which decreased to normal levels following the 4-month washout period. When therapy with L-carnitine was resumed, intravenous administration or in dialysate, the muscle carnitine levels remained within the normal range. Similarly, serum carnitine was markedly elevated at baseline and decreased to normal during the washout period. When L-carnitine was added to the dialysate, total carnitine was observed to significantly increase in the group receiving 4 g.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1989

Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study.

A double-blind, crossover study was designed to evaluate the effect of L-carnitine on the reactive hyperemia in patients with peripheral vascular disease. After drug washout, 18 patients were randomly assigned to receive placebo or L-carnitine, 3 g IV as a bolus, followed by continuous intravenous infusion of 2 mg/kg/min for thirty minutes. Blood flow in the affected limb was measured by impedance plethysmography, under resting conditions and every two minutes for ten minutes after a five-minute ischemia induced in the affected limb. As compared with placebo, L-carnitine did not modify blood flow at rest. On the contrary, the hyperemic response with carnitine was higher than that observed with placebo. A significant increase in blood flow was found two, four, and six minutes after the release of ischemia with placebo, whereas the blood perfusion to the affected limb rose significantly at all times of recording after carnitine administration. Moreover, the values of the blood flow at two and ten minutes with carnitine were significantly higher than those recorded after placebo at the same times of recording. After the release of ischemia, the mean maximum value of blood flow observed after carnitine was 3.1 +/- 1.4 mL/min/100 mL, a value significantly higher than that recorded after placebo, which was 2.7 +/- 1.3 mL/min/100 mL (p less than 0.05). In conclusion, this study demonstrates that L-carnitine, although not affecting blood flow and ankle/arm systolic blood pressure ratio under resting conditions, improves the functional circulatory reserve in patients with peripheral vascular disease.

Carnitine↗
PubMed1988

Fine structure of the receptors at the myotendinous junction of human extraocular muscles.

The myotendinous junction of the human extraocular muscles was studied by electron microscopy. Some peculiar receptorial structures have been found in the majority of the samples examined. These structures are very small and consist of 1) the terminal portion of one muscle fibre, 2) the tendon into which it inserts and 3), within the tendon, a rich nerve arborization, whose branches are always very close to the muscle component. Only one discontinuous layer, made up of flat cells, which lack a basal lamina and often show pinocytotic vesicles, encapsules every musculo-tendinous complex. The tendinous component consists of amorphous ground substance of different electron density, of collagen and elastic fibres and is divided in compartments by ramified cells, which make an inner capsular-like covering to the nerve fibres. Three types of afferent nerve endings can be identified. One type is usually more frequent than the others, possesses a large number of neurotubules and neurofilaments and few mitochondria and is always surrounded by a Schwann cell which forms finger-like processes penetrating into the axoplasm. The second type is only partially enveloped by the Schwann cell. The axoplasm is devoid of neurotubules and contains few neurofilaments, several mitochondria and groups of small clear vesicles placed in the areas uncovered by the glial sheath. The third one is completely surrounded by the Schwann cell, but is devoid of neurotubules and neurofilaments and full of mitochondria. These morphological features correspond well with the probable role of these receptorial structures, which is to ensure very exact and precise ocular movements.

Adult↗
PubMed1988

Plasma and urine pharmacokinetics of free and of short-chain carnitine after administration of carnitine in man.

To 6 healthy volunteers 30 mg/kg of L-carnitine (1,3-hydroxy-4-N-trimethylamino-butyrate) were injected intravenously and plasma levels (mumol/l) of free and short-chain carnitine were determined at different times between 0.033 and 24 h. The urinary excretion of L-carnitine and short-chain carnitine in 24 h was also measured. After a period of wash-out the subjects received 100 mg/kg of L-carnitine orally and plasma levels were determined between 0.5 and 24 h. The urinary excretion of L-carnitine was measured for a period of 18.5-33 h after treatment. 3 of the volunteers also received 30 mg/kg of L-carnitine orally. Carnitine plasma levels were determined at different times between 0.5 and 18 h, while the urinary excretion of L-carnitine was measured for 48 h following the treatment. The results could indicate the presence of saturation phenomena in the absorption process for the oral doses used; specific research is required to ascertain this phenomena. The transfer of carnitine from central to extravascular volume is relatively rapid, as is its urinary excretion. The short half-life of carnitine and acetyl-carnitine can suggest the use of new forms of administration (slow-release).

Administration, Oral↗
PubMed1988

[Hepatic echography in acute viral hepatitis].

Reports on cholecystic alterations during acute viral hepatitis are more and more frequent; the pathogenesis and clinical meaning of these alterations are still debated. Consensual periportal lymphnode enlargement has been not yet reported. The authors describe four cases of acute viral hepatitis in which US showed alterations of cholecystic walls and/or contents; in two cases enlarged periportal lymphnodes were demonstrated too. Later US exams showed a complete regression of both cholecystic and lymphnodal lesions. Clinical findings and laboratory out-comes are evaluated; the connection of US results with hepatitis and its meaning are discussed. The causes of cholecystic alterations are still questionable; they might be related to blood disorders or to an increased portal pressure, or else they might be considered as phlogistic lesions. The authors conclude that both cholecystic and lymphnodal alterations have a phlogistic nature; moreover, they are not related to a particular evolution of hepatitis. The importance of distinguishing cholecystic alterations from different pathologies is stressed.

Adult↗
PubMed1983

Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients.

A group of 14 uremic patients on intermittent hemodialysis was admitted to a cross-over double-blind trial in order to evaluate serum and muscle carnitine levels before and after 60 days of L-carnitine oral (2 g/day) treatment. The morphology of muscle fragments was studied by light and electron microscopy. Symptoms (asthenia, cramps) occurring during hemodialysis were also recorded. After L-carnitine treatment the blood and muscle levels of the metabolite increased simultaneously to reduced asthenia and cramps. Morphological examination of the muscle of 13 of 14 patients did not reveal any pre- or posttreatment pathological alterations. The presence of nemaline rods was morphologically diagnosed in only one case and was no longer observed at the second biopsy at 2 months of L-carnitine treatment.

Adult↗
PubMed1983

Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol.

Twenty-nine hemodialyzed patients with hypertriglyceridemia were given L-carnitine (20 mg/kg iv at the end of each dialysis) for 120 days and then placebo for the same duration in order to evaluate the lipid-lowering effects of the metabolite. A dramatic reduction in triglyceride levels was observed only in the group of patients (n = 12) with high basal triglyceride values, low levels of high-density lipoprotein-cholesterol, and with apoprotein A at the lower limit of normal range. During L-carnitine treatment these patients exhibited significantly increased high-density lipoprotein-cholesterol and apoprotein A. No rebound effects were observed. L-Carnitine did not provoke changes in the lipid parameters in the group (n = 17) with high basal triglyceride values, and normal high-density lipoprotein-cholesterol and apoprotein A. Hematocrit values increased in all the 29 patients during L-carnitine treatment. At the end of the experimental protocol, L-carnitine dosage was increased to 60 mg/kg iv (at the end of each dialysis) in four patients of the group of nonresponders and prolonged for 60 days. This produced a considerable reduction in triglyceride levels. The above results suggest that L-carnitine can be effective in the management of hypertriglyceridemia in the hemodialyzed patient especially when low high-density lipoprotein-cholesterol levels are present.

Adult↗
PubMed1983

Plasma and muscle carnitine levels in haemodialysis patients with morphological-ultrastructural examination of muscle samples.

The present study investigates 14 patients on intermittent haemodialysis. Pre-dialysis blood and muscle samples taken for determining plasma free- and acetylcarnitine levels. The tissue fragments were used for light and electron microscopy studies. Our results support the findings of other investigators that patients on haemodialysis generally display decreased free- and acetylcarnitine levels both in plasma and skeletal muscle when compared with control values. Muscle carnitine deficiency was apparently more severe in the longer-term haemodialysis patients. Moreover, a significant correlation (p less than 0.05) between plasma and muscle free-carnitine values was found. Morphologically no pathological alterations were observed in the muscle fibres in 13 of the patients. Light and electron microscopic studies of the muscle fibre of the 14th patient showed a typical nemaline myopathy with rod bodies in the cytoplasm. The muscle free-carnitine concentration in this patient was among the lowest of the group.

Adult↗